Barclays’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q1 | – | Sell |
-6,100
| Closed | -$30K | – | 7271 |
|
|
2016
Q4 | $30K | Buy |
+6,100
| New | +$31.2K | ﹤0.01% | 5443 |
|
|
2016
Q3 | – | Sell |
-200
| Closed | -$1K | – | 7100 |
|
|
2016
Q2 | $1K | Sell |
200
-2,200
| -92% | -$11.8K | ﹤0.01% | 6275 |
|
|
2016
Q1 | $12K | Buy |
+2,400
| New | +$16.8K | ﹤0.01% | 5433 |
|
|
2015
Q3 | – | Sell |
-600
| Closed | -$11K | – | 7461 |
|
|
2015
Q2 | $11K | Sell |
600
-16,600
| -97% | -$294K | ﹤0.01% | 6064 |
|
|
2015
Q1 | $292K | Buy |
17,200
+14,100
| +455% | +$237K | ﹤0.01% | 4059 |
|
|
2014
Q4 | $47K | Buy |
3,100
+1,000
| +48% | +$13.4K | ﹤0.01% | 5785 |
|
|
2014
Q3 | $25K | Sell |
2,100
-9,900
| -83% | -$141K | ﹤0.01% | 6361 |
|
|
2014
Q2 | $180K | Sell |
12,000
-3,000
| -20% | -$44.1K | ﹤0.01% | 4920 |
|
|
2014
Q1 | $195K | Sell |
15,000
-5,700
| -28% | -$89.2K | ﹤0.01% | 4818 |
|
|
2013
Q4 | $331K | Sell |
20,700
-1,600
| -7% | -$25.5K | ﹤0.01% | 4501 |
|
|
2013
Q3 | $357K | Buy |
22,300
+9,700
| +77% | +$143K | ﹤0.01% | 4463 |
|
|
2013
Q2 | $127K | Buy |
+12,600
| New | +$132K | ﹤0.01% | 5596 |
|
Other funds holding OSIR
Barclays's OSIR Position: Q2 2019 in Review
Barclays sold out of Osiris Therapeutics, Inc. Common Stock (OSIR) in Q2 2019, closing a stake of 82,690 shares — an estimated $1.57M sold.
Barclays first reported a position in OSIR in Q2 2013 and held it in 18 quarters. The position peaked at $1.57M in Q1 2019. 1 fund tracked by Wall St. Rank holds OSIR as of Q2 2019.
- Barclays reported no remaining Osiris Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
- Barclays sold 82,690 Osiris Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $1.57M.
- Barclays first reported a position in Osiris Therapeutics, Inc. Common Stock in Q2 2013 and held it in 18 quarters.
- Barclays's Osiris Therapeutics, Inc. Common Stock position peaked at $1.57M in Q1 2019.
- 1 fund tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q2 2019.
Based on Barclays's 13F filing for Q2 2019, filed 14 Aug 2019.